ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,203.70
0.95%
S&P ASX All Technology
3,433.00
1.97%
Brent Oil
70.865
-3.18%
US Dollar vs AUD
1.45151
-0.99%
Bitcoin
65,202.55
3.27%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCCP)

  7. Cyclacel Pharmaceuticals Inc (CYCCP) News

CYCCP

Cyclacel Pharmaceuticals (CYCCP)

Cyclacel Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYCCP
DateTimeSourceHeadlineSymbolCompany
25/09/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudyNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/09/202406:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
04/09/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
03/09/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/08/202423:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
27/08/202407:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
23/08/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
15/08/202407:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
15/08/202406:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/08/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
01/08/202406:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
26/06/202423:15GlobeNewswire Inc.Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
04/06/202422:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
03/06/202422:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
17/05/202423:56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
15/05/202407:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
15/05/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
15/05/202406:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202406:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202411:56Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202411:53Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202411:52Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/05/202407:26Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
03/05/202406:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
01/05/202403:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202421:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
02/04/202400:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
20/03/202407:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CYCCP

Your Recent History

TG
14N1
Rithm Capital
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved